

CSPC Pharmaceutical (1093 HK)

Legacy products faced pricing pressures

- Moderate growth in 1H24.** In 1H24, CSPC's total revenue increased by 1.3% YoY to RMB16.28bn and the attributable net profit increased by 1.8% YoY to RMB3.02bn, accounting for 46% and 45% of our previous full-year estimates. For 2Q24, the total revenue was RMB5.99bn (-8.1% YoY, -20.8% QoQ) and the attributable net profit was RMB2.19bn (+42.2% YoY, +35.7% QoQ). The net profit increase was mainly due to the reduced selling expenses in 2Q24, which decreased by 38.6% QoQ to RMB1.82bn. GP margin in 1H24 improved to 71.6% (up from 69.9% in 1H23), due to a higher proportion of revenue from finished drugs. R&D expenses reached RMB1.37bn in 2Q24 (+17.4% QoQ).
- Jinyouli and Duomeisu may face pricing pressures.** The company recorded RMB5.99bn in sales from finished drugs in 2Q24 (-8.1% YoY, -20.8% QoQ). The sales of oncology products, cardiovascular drugs, and respiratory disease products decreased by 30.6%, 27.0%, and 23.1% YoY in 2Q24 to RMB1.07bn, RMB509mn, and RMB289mn, respectively. Significant price cuts in the "3+N" Alliance provincial VBP, effective Mar 2024, impacted the sales of oncology products, with the price of Jinyouli reduced by 58.4% to RMB666 (3mg) and Duomeisu by 10.0% (10mg) to RMB2,061 and 21.8% (20mg) to RMB3,504. With more provinces adopting these reduced prices, sales of Jinyouli and Duomeisu are expected to continue to decline. Additionally, Duomeisu is likely to be included in the upcoming national VBP. However, NBP performed well in 1H24, driven by strong growth from retail pharmacy channels, with sales of CNS products increased by 4.2% YoY to RMB2.53bn.
- Sales target of new products adjusted downward.** Affected by the regulatory environment in China, the company expects certain delays in hospital listings of its new products, and thus revised down its FY24 sales target for new products from RMB3.0bn to RMB2.0bn (excl. channel inventory build-up). Nevertheless, we expect the sales ramp-up of new products to continue in 2H24 and 2025, including Mingfule (rhTNK-tPA), Duoenyi (irinotecan liposome), Anfulike (amphotericin B), etc, which could help offset the decline in oncology products. By end-2024, we expect the company to bring four assets to the NRDL, including narlumobart (RANKL), enlonstobart (PD-1), Duoenyi (irinotecan liposome) and palbociclib (CDK4/6). We expect the addition of a new indication for Mingfule for acute ischemic stroke during the NRDL negotiation at end-2024, bringing additional sales potential for the product. NBP will also renew its NRDL price by end-2024.
- Maintain BUY.** Due to the moderate 1H24 growth, pricing pressures of legacy products, and downward revision of new product sales target, we revised our estimate and expect CSPC's revenue and attributable net profit to grow 1.3%/1.3% and 0.5%/-1.5% YoY in FY24E/ 25E, respectively. We revise down our DCF-based TP from HK\$8.51 to HK\$6.21 (WACC 11.78%, terminal growth 2.0%).

Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	30,937	31,450	31,853	32,278	33,782
YoY growth (%)	11.0	1.7	1.3	1.3	4.7
Net profit (RMB mn)	6,232	6,073	5,963	5,873	6,257
YoY growth (%)	9.6	(2.6)	(1.8)	(1.5)	6.5
EPS (Reported) (RMB)	0.51	0.49	0.50	0.49	0.52
P/E (x)	8.7	9.0	8.9	9.1	8.5
Net gearing (%)	(44.1)	(37.3)	(41.2)	(45.8)	(49.3)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$6.21
(Previous TP)	HK\$8.51)
Up/Downside	27.8%
Current Price	HK\$4.86

China Healthcare

Jill WU, CFA

(852) 3900 0842
jillwu@cmbi.com.hk

Andy WANG

(852) 3657 6288
andywang@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	57,917.6
Avg 3 mths t/o (HK\$ mn)	250.5
52w High/Low (HK\$)	7.33/4.86
Total Issued Shares (mn)	11917.2

Source: FactSet

Shareholding Structure

Massive Giant Group Ltd	10.2%
Cai Dongchen	10.0%


Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	-20.1%	-20.1%
3-mth	-25.3%	-18.8%
6-mth	-23.7%	-27.6%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Risk-adjusted DCF valuation

DCF Valuation (in RMB mn)	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E
EBIT	7,560	7,443	7,666	7,858	8,015	8,175	8,298	8,381	8,423
Tax rate	19.72%	19.72%	19.72%	19.72%	19.72%	19.72%	19.72%	19.72%	19.72%
EBIT*(1-tax rate)	6,069	5,975	6,154	6,308	6,434	6,563	6,662	6,728	6,762
+ D&A	1,114	1,114	1,148	1,176	1,200	1,224	1,242	1,255	1,261
- Change in working capital	-665	-15	-15	-16	-16	-17	-17	-17	-17
- Capex	-1,624	-1,624	-1,624	-1,624	-1,624	-1,624	-1,624	-1,624	-1,624
FCFF	4,895	5,451	5,663	5,845	5,994	6,147	6,263	6,342	6,382
Terminal value									66,543

Terminal growth rate	2.00%
WACC	11.78%
Cost of Equity	15.08%
Cost of Debt	5.00%
Equity Beta	1.15
Risk Free Rate	3.00%
Market Risk Premium	10.50%
Target Debt to Asset ratio	30.00%
Effective Corporate Tax Rate	18.00%

Terminal value (RMB mn)	21,846
Total PV (RMB mn)	52,785
Net debt (RMB mn)	-15,378
Minority interests (RMB mn)	1,850
Equity value (RMB mn)	66,313
# of shares (mn)	11,860

DCF per share (in HK\$) **6.21**

Source: CMBIGM estimates

Figure 2: Sensitivity analysis (HK\$)

		WACC				
		10.78%	11.28%	11.78%	12.28%	12.78%
Terminal growth rate	3.00%	7.13	6.78	6.47	6.19	5.94
	2.50%	6.94	6.62	6.33	6.08	5.84
	2.00%	6.78	6.48	6.21	5.97	5.75
	1.50%	6.63	6.35	6.10	5.88	5.67
	1.00%	6.50	6.24	6.00	5.79	5.59

Source: Company data, CMBIGM estimates

Figure 3: CMBIGM estimates - new vs old

RMB mn	NEW			OLD			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	31,853	32,278	33,782	35,065	38,970	43,325	-9.2%	-17.2%	-22.0%
Gross profit	22,864	23,079	24,154	25,301	27,764	31,194	-9.6%	-16.9%	-22.6%
Operating profit	7,560	7,443	7,908	8,325	9,112	10,479	-9.2%	-18.3%	-24.5%
Attributable net profit	5,903	5,814	6,194	6,642	7,269	8,366	-11.1%	-20.0%	-26.0%
EPS (RMB)	0.50	0.49	0.52	0.56	0.61	0.70	-10.7%	-19.6%	-25.6%
Gross margin	71.78%	71.50%	71.50%	72.15%	71.25%	72.00%	-0.37ppt	+0.25ppt	-0.5ppt
Operating margin	23.74%	23.06%	23.41%	23.74%	23.38%	24.19%	0ppt	-0.32ppt	-0.78ppt
Net margin	18.53%	18.01%	18.33%	18.94%	18.65%	19.31%	-0.41ppt	-0.64ppt	-0.98ppt

Source: Company data, Bloomberg, CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

RMB mn	CMBI			Consensus			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	31,853	32,278	33,782	32,525	34,278	36,635	-2.1%	-5.8%	-7.8%
Gross profit	22,864	23,079	24,154	23,276	24,567	26,368	-1.8%	-6.1%	-8.4%
Operating profit	7,560	7,443	7,908	7,585	7,962	8,517	-0.3%	-6.5%	-7.2%
Attributable net profit	5,903	5,814	6,194	6,198	6,402	6,807	-4.8%	-9.2%	-9.0%
EPS (RMB)	0.50	0.49	0.52	0.52	0.54	0.58	-4.7%	-9.7%	-10.4%
Gross margin	71.78%	71.50%	71.50%	71.56%	71.67%	71.97%	+0.22ppt	-0.17ppt	-0.47ppt
Operating margin	23.74%	23.06%	23.41%	23.32%	23.23%	23.25%	+0.41ppt	-0.17ppt	+0.16ppt
Net margin	18.53%	18.01%	18.33%	19.06%	18.68%	18.58%	-0.53ppt	-0.67ppt	-0.25ppt

Source: Company data, Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Revenue	27,867	30,937	31,450	31,853	32,278	33,782
Cost of goods sold	(6,732)	(8,680)	(9,273)	(8,989)	(9,199)	(9,628)
Gross profit	21,135	22,256	22,177	22,864	23,079	24,154
Selling expense	(10,443)	(10,337)	(9,141)	(9,370)	(9,619)	(9,966)
Admin expense	(1,010)	(1,173)	(1,190)	(1,238)	(1,194)	(1,233)
R&D expense	(3,433)	(3,987)	(4,830)	(5,033)	(5,164)	(5,405)
Others	546	815	421	337	342	358
Operating profit	6,795	7,574	7,437	7,560	7,443	7,908
Gain/loss on financial assets at FVTPL	0	0	0	0	0	0
Share of (losses)/profits of associates/JV	60	33	(21)	(103)	(100)	(100)
Net Interest income/(expense)	(8)	(25)	(26)	(28)	(27)	(13)
Pre-tax profit	6,847	7,582	7,389	7,428	7,316	7,795
Income tax	(1,159)	(1,350)	(1,317)	(1,465)	(1,443)	(1,537)
Minority interest	83	141	199	61	60	64
Net profit	5,688	6,232	6,073	5,963	5,873	6,257
Gross dividends	1,691	2,097	2,726	1,771	1,744	1,858
Net dividends	9	9	(4)	0	(2)	7

BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Current assets	20,337	23,957	26,745	30,102	33,869	38,115
Cash & equivalents	9,284	10,298	12,015	14,980	18,531	22,118
Account receivables	3,890	4,631	6,542	6,981	7,075	7,404
Inventories	2,480	2,555	3,139	3,042	3,114	3,259
Prepayment	0	0	0	0	0	0
ST bank deposits	1,443	3,575	1,077	1,077	1,077	1,077
Other current assets	3,240	2,898	3,972	4,021	4,073	4,257
Non-current assets	14,405	17,813	19,537	20,047	20,556	21,066
PP&E	8,529	9,582	10,417	11,173	11,929	12,686
Deferred income tax	43	113	187	187	187	187
Intangibles	468	1,908	2,199	2,116	2,033	1,950
Goodwill	1,035	1,395	1,226	1,062	898	734
Financial assets at FVTPL	1,979	2,126	2,387	2,387	2,387	2,387
Other non-current assets	2,351	2,689	3,122	3,122	3,122	3,122
Total assets	34,742	41,770	46,282	50,149	54,425	59,181
Current liabilities	7,226	8,958	10,183	9,882	10,056	10,438
Short-term borrowings	0	153	450	422	395	367
Account payables	6,162	6,864	8,404	8,147	8,337	8,726
Tax payable	261	262	379	379	379	379
Other current liabilities	803	1,679	948	934	945	967
Non-current liabilities	687	1,170	1,082	1,082	1,082	1,082
Long-term borrowings	0	0	0	0	0	0
Other non-current liabilities	687	1,170	1,082	1,082	1,082	1,082
Total liabilities	7,913	10,128	11,264	10,964	11,137	11,520
Share capital	10,899	10,899	10,899	10,899	10,899	10,899
Other reserves	15,087	19,298	22,304	26,436	30,505	34,841
Total shareholders equity	25,987	30,198	33,203	37,335	41,404	45,740
Minority interest	842	1,444	1,815	1,850	1,883	1,921
Total equity and liabilities	34,742	41,770	46,282	50,149	54,425	59,181

CASH FLOW	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	6,847	7,582	7,389	7,428	7,316	7,795
Depreciation & amortization	865	1,048	1,114	1,114	1,114	1,114
Tax paid	(1,141)	(1,335)	(1,309)	(1,465)	(1,443)	(1,537)
Change in working capital	(1,388)	798	(3,032)	(665)	(15)	(248)
Others	(547)	(467)	16	0	0	0
Net cash from operations	4,637	7,627	4,179	6,413	6,972	7,123
Investing						
Capital expenditure	(1,410)	(2,220)	(1,624)	(1,624)	(1,624)	(1,624)
Acquisition of subsidiaries/ investments	0	0	0	0	0	0
Others	773	(4,576)	2,231	0	0	0
Net cash from investing	(637)	(6,796)	607	(1,624)	(1,624)	(1,624)
Financing						
Dividend paid	(1,691)	(2,097)	(2,726)	(1,771)	(1,744)	(1,858)
Net borrowings	0	486	0	0	0	0
Proceeds from share issues	0	0	0	0	0	0
Share repurchases	(264)	(14)	(200)	0	0	0
Others	(242)	(279)	626	(54)	(54)	(54)
Net cash from financing	(2,197)	(1,904)	(2,301)	(1,825)	(1,798)	(1,912)
Net change in cash						
Cash at the beginning of the year	7,259	9,060	10,298	12,015	14,980	18,531
Exchange difference	(2)	14	5	0	0	0
Others	0	0	0	0	0	0
Cash at the end of the year	9,060	8,001	12,015	14,980	18,531	22,118
GROWTH	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Revenue	11.7%	11.0%	1.7%	1.3%	1.3%	4.7%
Gross profit	13.1%	5.3%	(0.4%)	3.1%	0.9%	4.7%
Operating profit	12.2%	11.5%	(1.8%)	1.7%	(1.6%)	6.2%
Net profit	8.8%	9.6%	(2.6%)	(1.8%)	(1.5%)	6.5%
PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Gross profit margin	75.8%	71.9%	70.5%	71.8%	71.5%	71.5%
Operating margin	24.4%	24.5%	23.6%	23.7%	23.1%	23.4%
Return on equity (ROE)	23.5%	22.2%	19.2%	16.9%	14.9%	14.4%
GEARING/LIQUIDITY/ACTIVITIES	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Net debt to equity (x)	(0.4)	(0.4)	(0.4)	(0.4)	(0.5)	(0.5)
Current ratio (x)	2.8	2.7	2.6	3.0	3.4	3.7
Receivable turnover days	92.9	87.7	120.5	124.6	124.6	124.6
Inventory turnover days	134.5	107.4	123.5	123.5	123.5	123.5
Payable turnover days	352.4	319.6	349.4	349.4	349.4	349.4
VALUATION	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
P/E	9.5	8.7	9.0	8.9	9.1	8.5
P/E (diluted)	9.5	8.7	9.0	8.9	9.1	8.5
P/B	2.0	1.7	1.5	1.3	1.2	1.1
P/CFPS	11.5	7.0	12.6	8.2	7.6	7.4
Div yield (%)	3.2	4.0	5.2	3.4	3.3	3.5

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.